https://sputnikglobe.com/20210303/russias-covid-vaccine-sputnik-v-green-lighted-for-use-in-angola-congo-djibouti-1082243621.html
Russia's COVID Vaccine Sputnik V Green-Lighted for Use in Angola, Congo, Djibouti
Russia's COVID Vaccine Sputnik V Green-Lighted for Use in Angola, Congo, Djibouti
Sputnik International
MOSCOW (Sputnik) - Angola, Djibouti and the Republic of Congo have officially authorized Russia's coronavirus vaccine Sputnik V for mass use, the Russian... 03.03.2021, Sputnik International
2021-03-03T13:33+0000
2021-03-03T13:33+0000
2022-11-24T11:28+0000
https://cdn1.img.sputnikglobe.com/img/07e5/03/01/1082223356_0:67:3119:1830_1920x0_80_0_0_f925c918f02e3487765c5db2a513332e.jpg
africa
russia
angola
djibouti
democratic republic of the congo
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
newsfeed, russia, russian direct investment fund (rdif), angola, djibouti, vaccine, democratic republic of the congo
newsfeed, russia, russian direct investment fund (rdif), angola, djibouti, vaccine, democratic republic of the congo
Russia's COVID Vaccine Sputnik V Green-Lighted for Use in Angola, Congo, Djibouti
13:33 GMT 03.03.2021 (Updated: 11:28 GMT 24.11.2022) MOSCOW (Sputnik) - Angola, Djibouti and the Republic of Congo have officially authorized Russia's coronavirus vaccine Sputnik V for mass use, the Russian Direct Investment Fund (RDIF) said on Wednesday.
"The Russian Direct Investment Fund ... announces the approval of the Russian Sputnik V vaccine against coronavirus by regulatory authorities of the Republic of Angola, Republic of Congo and Republic of Djibouti. Sputnik V has been registered under the emergency use authorization procedure," the RDIF said in a statement.
The Russian vaccine has now been approved for emergency use in 42 countries across the world.
In February, peer-reviewed medical journal
The Lancet published an interim analysis from Phase III clinical trial of the Russian vaccine, showing its 91.6-percent efficacy against symptomatic COVID-19.
Developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V was the world's first officially-registered vaccine against COVID-19.
